ESC 365 - Effect of alirocumab on recurrent cardiovascular events after acute coronary syndrome, according to the intensity of background statin treatment

ESC Premium Access

Effect of alirocumab on recurrent cardiovascular events after acute coronary syndrome, according to the intensity of background statin treatment

Session: Progress in secondary prevention - New treatments

Topic: Drug therapy

Speaker: Doctor R. Diaz (Rosario, AR)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Doctor Rafael Diaz

Estudios Cardiologicos Latinoamerica (ECLA), Rosario (Argentina)

2 presentations

0 follower

4 more presentations in this session

Association of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors with cardiovascular events stratified by renal function: a network meta-analysis

Speaker: Mr A. Roddick (Oxford, GB)

Risk factors and clinical outcomes in chronic CAD and PAD: an analysis of the randomized, double-blind COMPASS trial

Speaker: Doctor T. Vanassche (Leuven, BE)

Glucose lowering drugs or strategies, major adverse cardiovascular events and heart failure outcomes, and association with weight loss - meta-analysis of large cardiovascular outcome trials

Speaker: Miss O. Ghosh-Swaby (London, CA)

Efficacy of alirocumab treatment after acute coronary syndrome according to new ACC/AHA guidelines for lipid-lowering therapy

Speaker: Professor M. Roe (Chapel Hill, US)

Access the full session

Progress in secondary prevention - New treatments

Speakers: Doctor R. Diaz, Mr A. Roddick, Doctor T. Vanassche, Miss O. Ghosh-Swaby, Professor M. Roe

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources